Stage III: Moderate kidney damage eGFR 30-59 mg/dL Declining kidney function with symptoms such as swelling in the hands and feet, pain in the back, and increased or decreased frequency of urination Accumulation of toxic nitrogenous substances called uremia (blood urea levels more than 45 mg/...
We classified the patients into four groups based on estimated glomerular filtration rate: stage 1/2 (normal to mild, n = 375), stage 3a (mild to moderate, n = 122), stage 3b (moderate to severe, n = 43), and stage 4/5 (severe to end﹕tage, n = 20) CKD. The relationship ...
There is limited real-world data evaluating outcomes of glucagon-like peptide-1 receptor agonists (GLP1-RA) use in patients with moderate to advanced CKD. Here, emulating a clinical trial, the authors show that GLP1-RA use in patients with CKD is associated with lower rate of acute healthca...
AstraZeneca has established a bold ambition to transform the lives of the estimated 37 million Americans living with chronic kidney disease (CKD) by addressing current gaps across the spectrum of the condition—from earlier diagnosis to late...
The top asso- ciations from the baseline model had moderate attenuation in significance, despite the similar effect sizes, due in part to the reduced sample size (Additional file 1: Table S5). In addition, a third GWAS was performed with APOL1 included as a covariate in the model (APO- ...
Given that the administration of a phosphate binder reduced circulating levels of FGF23 in CKD rats,22 the previous observation that dietary phosphate restriction reversed the low 1,25(OH)2D levels in patients with moderate CKD23 can be interpreted as a result of a decrease in circulating levels...
The most frequent AEs in stage 3b–5 and stage 1–3a CKD patients, respectively, were constipation (7.8% and 2.8%) and diarrhoea (4.0% and 1.9%); all cases were mild or moderate in severity. AEs leading to patiromer discontinuation occurred in 5.7% and 2.4% of stage 3b–5 CKD and ...
CKD data analysis mostly analyze the early-stage subjects directly, but few studies have discussed the predictive models and important risk factors for the stage-III CKD high-risk health screening population. The middle stages 3a and 3b of CKD indicate moderate renal failure. This study aims to ...
In addition, recent evidence suggests that resistin levels can even predict cardiovascular hospitalizations in the type 2 diabetic population with mild to moderate CKD [13]. Therefore, this study aims to investigate the correlation of resistin levels and PAD in non-dialysis CKD stage 3 to 5 ...
Background: Patients with end-stage renal disease (ESRD) require specialized therapeutic interventions. The decreased renal function that modulates the physiology and presence of comorbidities is often associated with variations in the pharmacological re